With Respiratory Season rapidly approaching the Northern Hemisphere, clinical laboratories must consider diagnostic strategies that produce maximum clinical utility, utilize efficient workflows, and minimize costs. Respiratory tract infections remain among the most common causes of morbidity worldwide, accounting for a significant proportion of outpatient visits, emergency care utilization, and hospital admissions. The etiologies are diverse, ranging from influenza and respiratory syncytial virus (RSV) to rhinovirus and atypical organisms. Clinical presentation alone is often insufficient for definitive diagnosis, as overlapping symptoms—fever, cough, sore throat, nasal congestion, and malaise—can result from multiple viral or bacterial agents. In this context, molecular respiratory panels have emerged as critical tools guiding clinical decision-making and laboratory efficiency.
Unlike traditional culture or antigen-based methods, molecular assays provide:
By consolidating diagnostic workflows, multiplex panels reduce the need for sequential testing and can play a central role in antimicrobial stewardship by limiting unnecessary antibiotic use1.
One area of ongoing complexity is the differentiation between rhinoviruses and enteroviruses. Both belong to the family Picornaviridae and share high sequence homology, particularly in conserved regions of the viral genome targeted by many multiplex PCR assays2. As a result, many respiratory panels can only report a combined “rhinovirus/enterovirus” result, rather than distinguishing between the two.
This limitation poses challenges for both clinicians and laboratory professionals. Table 1 summarizes common clinical syndromes associated with each. While rhinoviruses are the leading cause of the common cold and are typically associated with mild upper respiratory tract infections, they can also exacerbate asthma and chronic obstructive pulmonary disease (COPD)3. Conversely, enteroviruses are capable of causing a much broader spectrum of illness, ranging from respiratory disease to severe systemic infections, including aseptic meningitis, myocarditis, and hand-foot-and-mouth disease4. In particular, outbreaks of enterovirus D68 have been associated with severe respiratory illness and, in some cases, acute flaccid myelitis in children5.
Table 1: Human Rhinovirus (RV) and Enterovirus (EV) subtypes and their associated clinical syndromes.
The inability to reliably distinguish these pathogens on many panels can lead to diagnostic uncertainty. From a laboratory perspective, it raises interpretive challenges when communicating results to clinicians, who may need to consider additional clinical or epidemiological information to guide patient management.
The clinical implications of identifying specific respiratory pathogens are significant:
To address the challenge of rhinovirus-enterovirus differentiation, some molecular platforms are incorporating expanded genomic targets or reflex assays. Sequencing-based approaches offer definitive resolution but may be impractical for routine diagnostics due to cost and turnaround time15. As panel technologies evolve, balancing assay breadth with clinically meaningful discrimination will be critical. Laboratories may also consider reflex testing strategies when enterovirus outbreaks are suspected, ensuring that results are actionable for both clinicians and public health authorities.
For laboratory professionals, understanding both the strengths and limitations of current panels is essential for accurate result interpretation, effective communication with clinicians, and optimal patient care. Ongoing innovation in assay design will continue to enhance the utility of these powerful diagnostic tools in addressing the dynamic landscape of respiratory infections.